Molecular point-of-care (mPOC) diagnostics are revolutionizing the in vitro diagnostics (IVD) landscape, delivering the sensitivity and specificity of molecular testing with the accessibility and speed of traditional point-of-care (POC) solutions. Kalorama Information's latest report, "Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029", provides a comprehensive analysis of this rapidly evolving market, covering the size, growth trajectory, and competitive dynamics forecasted over a five year span to 2029.
Market Drivers & Opportunities
mPOC has transitioned from an emerging innovation to a major market force, driven by increasing demand for rapid and accurate diagnostic solutions in critical care units, outpatient clinics, physician offices, and community health settings. The COVID-19 pandemic accelerated adoption, particularly in the respiratory testing segment, but the market continues to expand into new areas, including hospital-acquired infections (HAIs), sexually transmitted infections (STIs), and tropical diseases.
With leading companies such as Abbott, Cepheid, bioMerieux, Roche, and QuidelOrtho competing in the space, this report explores key questions:
What is the size and projected growth of the mPOC market?
Which companies are leading the market, and how are they positioned?
How is mPOC impacting traditional laboratory-based molecular testing?
What regions and disease segments present the greatest opportunities?
Comprehensive Market Insights
This report offers detailed segmentation of the mPOC market, including:
Market Sizing & Forecasts (2024-2029) - Revenue projections by technology, region, and disease area.
Competitive Analysis - Market share breakdowns and insights into leading companies.
Geographic Trends - Market distribution across North America, Europe, Asia Pacific, and the Rest of the World.
Technology & Regulatory Landscape - Overview of CLIA-waived and moderate-complexity molecular platforms.
Scope
"Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029" provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings. This Kalorama Information report provides real-world analysis and modeling for relevant circumstances, with insights into near-patient molecular testing using small instruments.
This comprehensive analysis includes market shares for companies, regions, and disease types, distinguishing between "true" molecular point-of-care and near-patient molecular systems. The report highlights the competitive landscape, with major IVD companies and innovative players contributing to the market's growth. The report defines molecular point-of-care (mPOC) devices as those that run PCR or other DNA and RNA testing on a portable device, with features such as small footprint, fast result times, and usability outside of a reference lab.
A Decade of mPOC Research Expertise
Kalorama Information has been covering the mPOC market since its inception and provides real-world analysis rooted in extensive primary and secondary research. Whether you are an IVD company, investor, or healthcare provider "Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029", offers critical insights to help you navigate and capitalize on this fast-growing segment.
Table 2-2: Deals in Molecular Point-of-Care, April 2019-Feb 2025
Advantages and Disadvantages of Molecular Point-of-Care
Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting [Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC]
Justification: The Sensitivity/Specificity Argument
New Systems and Menu Expansion
New Systems Introduced in Development
Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV
STI Continues to Be a Growth Area
Deals, Investment in mPOC Systems
Roche Acquires LumiraDx for up to $350 Million
Thermo Acquires Mesa Biotech
China as a POC Market
Common Tests and Analytes in POC Diagnostics
Component Technologies of Molecular Point-of-Care Diagnostics
Microfluidics
qPCR
Microarrays
Isothermal Amplification
Test Automation
Primers and Probes
Detection
Next-Generation Sequencing
Molecular Diagnostics
Real-Time PCR (qPCR)
Isothermal Amplification Methods
Loop-Mediated Isothermal Amplification (LAMP)
Nicking Enzyme Amplification Reaction (NEAR)
Strand Displacement Amplification (SDA)
Helicase Dependent Amplification (HDA)
Nucleic Acid Sequence-Based Amplification (NASBA)
Transcription-Mediated Amplification (TMA)
Cross Priming Amplification (CPA)
Line Probe Assays
Applications and Potential Applications for Molecular Point-of-Care
Major Testing Applications for Molecular POC Diagnostics